MIN-117 (known formerly as WF-516) is an investigational antidepressant which is under development by Minerva Neurosciences for the clinical treatment of major depressive disorder (MDD).
It is described as a 5-HT1A receptor, 5-HT
1A and 5-HT2A receptor, 5-HT
2A receptor receptor antagonist, antagonist and reuptake inhibitor, inhibitor of serotonin and dopamine reuptake,
and is also reported to possess affinity (pharmacology), affinity for the alpha-1A adrenergic receptor, α
1A- and alpha-1B adrenergic receptor, α
1B-adrenergic receptors.
As of May 2015, MIN-117 is in Phases of clinical research#Phase II, phase II clinical trials for MDD.
In December 2019, Minerva announced that MIN-117 was no longer in clinical development for MDD after disappointing results in a phase IIb trial.
See also
* List of investigational antidepressants
References
External links
MIN-117 - Minerva NeurosciencesInvestor Presentation March 2015 - Minerva NeurosciencesMIN-117 - AdisInsight
4-Phenylpiperidines
5-HT1A antagonists
5-HT2A antagonists
Antidepressants
Benzofuran ethers at the benzene ring
Serotonin–dopamine reuptake inhibitors
{{nervous-system-drug-stub